By Michael Erman

(Reuters] – America could start administering Pfizer BioNTech and NYSE: BioNTech will be distributing BioNTech’s COVID-19 vaccination to children ages five to eleven as soon as Wednesday. This is after a panel consisting of outside experts voted Tuesday to determine how widely the U.S. Centers for Disease Control and Prevention should recommend that it be used in this age group.

On Friday, the U.S. Food and Drug Administration gave emergency authorization for the vaccine to the age group. However, Rochelle Walensky (CDC Director) must provide her suggestions before the vaccine can be rolled-out.

Walensky will consider the vote by the CDC’s Advisory Committee on Immunization Practices. However, Walensky ignored their advice last month when she made a wider recommendation to Pfizer COVID-19 for booster doses. This was contrary to what the panel had recommended.

The FDA approval was granted and the U.S. government began to distribute the vaccine. This preparation allowed for an extensive rollout of the vaccine for children. Many are now back at school, allowing them to continue their education.

At a Monday press conference, Jeff Zients, White House Coronavirus Response Coordinator, stated that several million doses would begin arriving in the local pediatricians, family physicians offices, pharmacies. They will also be delivered to rural clinics, pharmacys, and community health centers.

Zients claimed that there is enough vaccine supply in the United States to cover all the 28 million children aged five through 11. Zients indicated that while some children could get their shots Wednesday, Zients confirmed that all of the vaccines for pediatrics in America will be available by week’s end.

Pfizer’s vaccine for young children was authorized by FDA to be administered in a 10mg dose. For those aged 12 or older, the original dose is 30 micrograms.

Last week, FDA advisors suggested that the FDA could reduce some side effects. They paid particular attention at their meeting to the incidence of myocarditis (heart inflammation) that was linked to Pfizer/BioNTech vaccines. Moderna (NASDAQ:) Mostly in young men.

Moderna’s teenage vaccine has yet to be approved by the FDA. This is while it studies myocarditis rates and other issues. Moderna announced on Sunday that it would delay seeking approval for its vaccine in younger children while the FDA reviews its application for authorization. This review could take up to January.

During Tuesday’s ACIP meeting, myocarditis issues will be also discussed.

According to CDC data, the incidence of COVID-19-related severe illnesses in children has been lower than that in adults. However, this is the eighth leading cause of death in children under eight years old in the United States.

COVID-19 vaccinations are not yet approved in other countries such as China, Cuba, the United Arab Emirates and Cuba.

USA: 58% are fully vaccinated. That is higher than in other countries, such as France and the UK.

It is possible that the number of shots given to young children may even be lower. U.S. vaccination rates for 12-15-year-olds are lower than those of other age groups, at 47%. Some parents who have been fully vaccinated may hesitate to immunize their children.

According to experts and public health officials, the states in America with high adult COVID-19 vaccine rates will be putting a lot of effort into getting children vaccinated.